HER2-targeted therapies - a role beyond breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• HER2 (human epidermal growth factor receptor 2) is a validated therapeutic target in breast cancer, with multiple agents approved.
• HER2 overexpression is also observed in various other solid tumors, including gastric, biliary tract, colorectal, non-small-cell lung, and bladder cancers.

Purpose of the Study:

• To review the current clinical applications of HER2-targeted therapies beyond breast cancer.
• To discuss the challenges and potential of novel HER2-targeted agents in other solid tumors.

Main Methods:

• Literature review of clinical trials and studies involving HER2-targeted therapies.
• Analysis of HER2 expression levels and gene alterations in various cancer types.
• Evaluation of treatment outcomes for HER2-targeted agents in different solid tumors.

Main Results:

• Trastuzumab improves survival in HER2-positive gastric cancer, establishing a standard of care.
• Other HER2-targeted agents (pertuzumab, lapatinib, T-DM1) have shown limited success in HER2-positive gastric cancer.
• HER2-targeted therapies are under investigation for biliary tract, colorectal, non-small-cell lung, and bladder cancers, with variable outcomes.

Conclusions:

• The efficacy of HER2-targeted therapies may not directly translate from breast cancer to other solid tumors due to biological differences.
• Further research and novel therapeutic strategies are needed to effectively target HER2 in other cancer types.
• Ongoing clinical development of new HER2-targeted agents holds promise for expanding treatment options.